Hisato Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hisato Ishii has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Akira Matsuno
Department of Neurosurgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara City, Chiba 299-0111, Japan
1 shared publication - Hajime Arai
Department of Neurosurgery, Juntendo University School of Medicine, Tokyo, Japan
1 shared publication - Tadayoshi Nakagomi
Teikyo University School of Medicine
1 shared publication - Takamitsu Fujimaki
Department of Neurosurgery, Teikyo University School of Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 4 August 2007
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 5 (1) , 89
Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases. Induction of O6-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been reported to suppress MGMT in an experimental glioma model. Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.
- 4 August 2007
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 5 (1) , 89
Open AccessEffectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma
Malignant gliomas recur even after extensive surgery and chemo-radiotherapy. Although a relatively novel chemotherapeutic agent, temozolomide (TMZ), has demonstrated promising activity against recurrent glioma, the effects last only a few months and drug resistance develops thereafter in most cases. Induction of O6-methylguanine-DNA methyltransferase (MGMT) in tumors is considered to be responsible for resistance to TMZ. Interferon-beta has been reported to suppress MGMT in an experimental glioma model. Here we report a patient with TMZ-refractory anaplastic astrocytoma (AA) who was treated successfully with a combination of interferon-beta and TMZ.